CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0183 (clinicaltrials.gov NCT No: NCT01590732)
Title:Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Principal Investigator:Michelle A. Fanale
Treatment Agent:Carboplatin; Etoposide; Ifosfamide; Romidepsin
Study Status:Open
Study Description:The goal of this clinical research study is find the highest tolerable dose of
romidepsin that can be given in combination with ifosfamide, carboplatin,
etoposide (ICE) to patients with PTCL. The safety of this drug combination will
also be studied.

Romidepsin is designed to stop the growth of cancer cells and block new blood
vessels from forming around the cancer cells. This may cause the cancer cells
to die.

Ifosfamide and etoposide are designed to slow or stop the growth of cancer
cells.

Carboplatin is designed to interfere with the growth of cancer cells by
stopping cell division, which may cause the cells to die.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I
Treatment Agents:Carboplatin
Etoposide
Ifosfamide
Romidepsin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Celgene Corp.
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2806
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults